那屈肝素钙治疗急性冠状动脉综合征的疗效观察

目的：评价那屈肝素钙治疗急性冠状动脉综合征的有效性和安全性。方法：137例急性冠状动脉综合征患者按随机原则平行分组后进行了阳性对照试验，对照药为依诺肝素钠。结果：治疗7d中，那屈肝素钙组未发生心脏死亡，依诺肝素钠组2例发生心脏死亡，差别无统计学意义（P〉0．05），第1～7天内两组均无心脏急性Q波心肌梗死。两组治疗前后CK，CKMB、肌钙蛋白T的改善均有统计学意义（P〈0．05），但是两组治疗前后的改善情况差别无统计学意义（P〉0．05）。治疗中偶见的不良反应为返酸和头晕，停药后好转。结论：那屈肝素钙和依诺肝素钠同样为一有效的急性冠状动脉综合征治疗药物，可以预防心脏死亡和心肌梗死，明显改善症状和检验指标，治疗中两药均无严重的不良反应。

Efficiency and Safety of Fraxiparin in the Treatment of Patients with ACS

Objective： To evaluate the efficiency and safety of fraxiparin in the treatment of patients with ACS. Method： 137 patients with acute coronary syndrome （ACS） were randomly assigned to fraxiparin treatment and enoxaparin treatment for 7 days. Result： 129 cases completed the whole trial and the results were obtained from ITT. The heart death rate was not statistically different between the two groups during the treatment. No Q segment acute myocardial infarction occurred. Both drugs statistically decreased CK CKMB and TnT. There was no significant difference between the two groups regarding these changes. Only two minor adverse reactions occurred and became normal soon after nadroparin withdrew. Conclusion： Fraxiparin and enoxaparin had similar efficiency and safety in the treatment of patients with ACS.